Investigational drug · Phase 2
PF-07976016
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "PF-07976016"
First trial start
2024
Dec 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-07976016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-07976016" as an intervention, largest first.
- A Study to Learn About the Study Medicine Called PF-07976016 in Adults With ObesityPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06717425 · 263 participants · Start Dec 9, 2024 · Primary completion Oct 23, 2025
Drug: PF-07976016; Placebo · For: Obesity
Sites: Anaheim, California; San Diego, California; Aurora, Colorado · 38 sites in all
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy AdultsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06106009 · 117 participants · Start Oct 27, 2023 · Primary completion Aug 19, 2024
Drug: PF-07976016; Placebo and 1 more · For: Healthy
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT06910839 · 21 participants · Start Mar 13, 2025 · Primary completion May 1, 2025
Drug: PF-07976016; PF-06882961 · For: Overweight; Obesity
Sites: Anaheim, California
PfizerPfizer (PFE)
NCT06670170 · 12 participants · Start Nov 5, 2024 · Primary completion Dec 24, 2024
Drug: PF-07976016 Formulation A; PF-07976016 Formulation B · For: Healthy Volunteers
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07015918 · 8 participants · Start Jun 4, 2025 · Primary completion Jul 16, 2025
Drug: [14C] PF-07976016; PF-07976016 and 1 more · For: Healthy Male Volunteers
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.